Topic Archives: Marc Lichtenfeld

Lichtenfeld’s “Killer Hiding in Your Medicine Cabinet” — what’s the “new breakthrough” that will lead to explosive profits?

The beginning of the latest ad from Marc Lichtenfeld’s Lightning Trend Trader is good and juicy, at the very least… how could you not open up the ad and pay attention? “The KILLER Hiding in Your Medicine Cabinet “These Common Drugs Take a Life Every 12 Minutes (Who’s at Risk?) “Here’s the NEW Breakthrough and […]

Lichtenfeld’s “Genesis Cure” — “This single technology could wipe 4,800 incurable diseases off the face of the Earth”

Fear Of Missing Out is such a big deal that it gets its own acronym in my book (FOMO — and a clever FOMO-fueling website here), and it drives investors to take huge chances just so they don’t have to worry about missing a chance at stupendous gains. That’s what many newsletter ads use to […]

Lichtenfeld: “I See a 4,150% Earnings Setup in This $6 Biotech”

This article originally ran on January 12… the teaser pitch was still being circulated heavily last week, and the stock released earnings on February 3 that disappointed investors, bringing shares down about 15% (it was teased as a “$7 biotech,” and briefly $8, before then). The original Jan. 14 “special event” catalyst teased by Lichtenfeld, […]

“How to Get Rich From the Cures on Demand Windfall” With Marc Lichtenfeld’s “Biggest Blockbuster of 2013”

Every biotech-related teaser ad promises that you can make life-changing profits while also curing the world of a dread disease, of course — that’s why we love ’em. But this one’s a little bit different — they are teasing a biotech company that is trying to develop new drugs, but according to the pitch this […]

Access Group (defunct)

Healthcare-focused newsletter, recommended stocks primarily of emerging device and biotech companies. Was helmed by Marc Lichtenfeld, who moved on to other publications, but stopped publishing after a short while — Lightning Trend Trader, a current publication of Lichtenfeld’s with The Oxford Club, sometimes covers biotech stocks.

Comments

  • Travis Johnson, Stock Gumshoe

    The two pitches we've looked at from Marc this year are about a fintech stock, ...

  • Avatar

    Marc Lichtenfeld doesn't care if he's right or wrong. Every loss I have is from his recommendations from the Oxford Club...

  • Avatar

    Has anyone had legit success with the lightning trade report?...

  • Avatar

    As far as me is concerned, any thing smelling at Oxford Club, I say NO THANKS, allthough Marc Lichtenfeld isn´t as bad ...

  • Travis Johnson, Stock Gumshoe

    Haven't written about Lichtenfeld's tease, but someone sent it to me today and it's clearly Ligand being touted as this ...

  • Avatar

    Unlike some other facets of the Oxford Club, the Income Letter, which focuses on dividend stocks, is a no nonsense knowl...

  • Avatar

    This is almost the same ad Marc Lichtenfeld from Oxford used in around 2012? to push Graftech (GTI). The same company Mi...

  • Avatar

    I would say Marc Lichtenfeld offered the 300,000% as a long term (retire on) potential if it was applied to all genetic...

  • Avatar

    This stock tease is back from Alexander Green and Oxford. Months Later. What is the deal, Travis? p.s. is the Marc...

  • Avatar

    I recently saw Marc Lichtenfeld at a Moneyshow where he was talking about high yield stocks in a low yield environment. ...

  • Avatar

    I just received a teaser from Marc Lichtenfeld (oxford communications / lightning trader for a stock that is not public ...

  • Avatar

    What do you think the Marc Lichtenfeld "How to play the first 100 day window" Trump Ten Trades may be?...

  • Travis Johnson, Stock Gumshoe

    I think that's probably the Marc Lichtenfeld promo I wrote about last month -- you can see the article here: http://www....

  • Avatar

    Gummies, Last week I gave you part 1 of "Why the Bull Market in Biotech Will Continue (Part 1 of 2) here... http://w...

  • Avatar

    $PDLI: For those who would happened to be in PDLI, Marc Lichtenfeld, Chief Income Strategist, at The Oxford Club has a n...

  • Avatar

    This from Marc Lichtenfeld at the Oxford Club: I will post part 2 once I get it. Not a compelling read but it is reassu...

  • Avatar

    Thomas: Found your comments interesting and informative - if only Oxford Club advertised its premium services something...

  • Avatar

    Greta: I'm not sure I see what the point is in trying to guess the 4 "great opportunities" being hyped by Marc Lichtenf...

  • Avatar

    Alison: Marc Lichtenfeld is talking about his results during the year 2013 - his "service" was actually called "Healthc...

  • Avatar

    My impression is that Marc Lichtenfeld (it's not Lichtenstein) of Oxford Club is a smart guy and works hard - but my adv...

  • Avatar

    Wow, First to comment! Too bad I don't have much to say about BDC's but I do like the back door way to potential IPO's ...

  • Avatar

    Marc Lichtenfeld is spouting off about a new top performing research service called Lightning Trends Trader. Anyone out...

  • Avatar

    I have never had First Access, but have been stung by Marc Lichtenfeld when he wrote about Accuray (ARAY) for Xcelerated...

  • Avatar

    Recently subscribed reader who is impressed and enjoys your site. Will probably become a paying subscriber very soon. ...

  • Avatar

    Thanks -- and good point on the "triple," though I think bypassing the fact that you need to put up collateral for a sho...

  • Avatar

    Thanks, Gumshoe. I got this teaser this week and it had me tempted, but I typed Marc Lichtenfeld into your search engin...

  • Avatar

    http://finance.yahoo.com/echarts?s=MELA#symbol=MELA;range=2y I'm just killing time between church & the BbQ at th...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch